您当前的位置:
首页 >
文章列表页 >
Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
Short communication | 更新时间:2023-08-29
    • Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma

    • Genes & Diseases   Vol. 10, Issue 5, (2023)
    • 作者机构:

      1. Department of Dermatology, University of Utah,UT,Salt Lake City,USA,84132

      2. Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,201900

      3. Shanghai Institute of Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125

      4. Department of Oral & Maxillofacial - Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China,200125

      5. Huntsman Cancer Institute,UT,Salt Lake City,USA,84112

      6. Department of Oncology, The Third People's Hospital of Zhengzhou

      7. ,Henan,Zhengzhou,China,450000

    • DOI:10.1016/j.gendis.2022.11.014    

      CLC:
    • Published:2023,

      Published Online:1 September 2023,

    扫 描 看 全 文

  • Ruixin Jiang, Xianbin Liang, Ye Tao, et al. Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. [J]. Genes & Diseases 10(5).(2023) DOI: 10.1016/j.gendis.2022.11.014.

  •  
  •  
查看原文

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0